Adma Biologics Gains On Launching Plasma Collection For Covid: 19 treatment
21/05/2020 17:15
** Shares of drug developer ADMA.O rise ~4% to $2.88 after
a subsidiary starts collection of convalescent plasma from
individuals who have recovered from COVID-19 urn:newsml:reuters.com:*:nGNX4NhkqJ
** People who have recovered have antibodies in their plasma
that may be helpful in treating the virus
** ADMA hopes to produce immune globulin, plasma-derived
medicine containing antibodies, to help currently ill patients
recover from the sometimes fatal respiratory disease
** Including session's gain, stock down ~28% YTD
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))